Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

Tirzepatide improves outcomes in patients with obesity-related HFpEF regardless of the severity of their baseline BMI or fat ...

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...